CA2629793A1 - Method to assess breast cancer risk - Google Patents

Method to assess breast cancer risk Download PDF

Info

Publication number
CA2629793A1
CA2629793A1 CA002629793A CA2629793A CA2629793A1 CA 2629793 A1 CA2629793 A1 CA 2629793A1 CA 002629793 A CA002629793 A CA 002629793A CA 2629793 A CA2629793 A CA 2629793A CA 2629793 A1 CA2629793 A1 CA 2629793A1
Authority
CA
Canada
Prior art keywords
breast cancer
adam
subject
risk
mmp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002629793A
Other languages
English (en)
French (fr)
Inventor
Marsha A. Moses
Susan Pories
David Zurakowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Beth Israel Deaconess Medical Center Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2629793A1 publication Critical patent/CA2629793A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002629793A 2005-11-16 2006-11-16 Method to assess breast cancer risk Abandoned CA2629793A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US73728105P 2005-11-16 2005-11-16
US60/737,281 2005-11-16
US84645606P 2006-09-22 2006-09-22
US60/846,456 2006-09-22
PCT/US2006/044684 WO2007059313A1 (en) 2005-11-16 2006-11-16 Method to assess breast cancer risk

Publications (1)

Publication Number Publication Date
CA2629793A1 true CA2629793A1 (en) 2007-05-24

Family

ID=37846993

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002629793A Abandoned CA2629793A1 (en) 2005-11-16 2006-11-16 Method to assess breast cancer risk

Country Status (6)

Country Link
US (1) US20090215102A1 (https=)
EP (1) EP1938105A1 (https=)
JP (1) JP2009515556A (https=)
AU (1) AU2006315348A1 (https=)
CA (1) CA2629793A1 (https=)
WO (1) WO2007059313A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2567079T3 (es) 2007-11-02 2016-04-19 Momenta Pharmaceuticals, Inc. Composiciones de polisacáridos que no son anticoagulantes
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8592393B2 (en) 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
RU2011102743A (ru) * 2008-06-26 2012-08-10 Дана-Фарбер Кэнсер Инститьют, Инк. (Us) Характерные признаки и детерминанты, связанные с метастазированием, и способы их применения
CN101738478A (zh) * 2008-11-27 2010-06-16 浙江大学 Mmp9作为卵巢癌的诊断标记物的用途
AU2010236222B2 (en) * 2009-04-16 2015-10-15 Momenta Pharmaceuticals, Inc. Methods of assessing activity of a polysaccharide composition
CA2796217A1 (en) * 2010-04-13 2011-10-20 The Trustees Of Columbia University In The City Of New York Biomarkers based on a multi-cancer invasion-associated mechanism
BR112012026542A2 (pt) 2010-04-16 2016-07-12 Momenta Pharmaceuticals Inc abordagem seletiva de tecido
CA2795868A1 (en) 2010-06-17 2011-12-22 Momenta Pharmaceuticals, Inc. Methods and compositions for modulating hair growth
JP5827323B2 (ja) * 2010-06-18 2015-12-02 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング ガン罹患の予測のためのバイオマーカー
EP2943585B1 (en) * 2013-01-09 2018-07-11 Friedrich-Alexander-Universität Erlangen-Nürnberg Method for in vitro detection and monitoring of a disease by measuring disease-associated protease activity in extracellular vesicles
JP2016520613A (ja) 2013-05-28 2016-07-14 モメンタ ファーマシューティカルズ インコーポレイテッド 薬学的組成物
US12320811B2 (en) 2014-05-09 2025-06-03 Ascendant Diagnostics, LLC Methods of detecting cancer
US10613090B2 (en) * 2014-05-09 2020-04-07 Ascendant Diagnostics, LLC Methods of detecting cancer
AU2018219247A1 (en) * 2017-02-08 2019-07-25 Silbiotech, Inc. Methods for determining breast cancer risk
US20190049455A1 (en) * 2017-08-11 2019-02-14 Panacea Pharmaceuticals Inc. HAAH and MMP-9 are Complementary Cancer Biomarkers and Predictors of Metastasis when Combined
CN114664435A (zh) * 2022-03-28 2022-06-24 上海交通大学医学院附属瑞金医院 先天性肾上腺皮质增生症诊断模型及其构建方法和应用
WO2024086792A2 (en) * 2022-10-21 2024-04-25 The Trustees Of Indiana University Methods for promoting homing and engraftment of hematopoietic stem cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITPD20030264A1 (it) * 2003-10-30 2005-04-30 Xeptagen Spa Metodo di diagnosi altamente specifico per neoplasie
AU2005207318B2 (en) * 2004-01-09 2012-02-02 Children's Medical Center Corporation Methods for diagnosis and prognosis of cancers of epithelial origin

Also Published As

Publication number Publication date
EP1938105A1 (en) 2008-07-02
US20090215102A1 (en) 2009-08-27
WO2007059313A1 (en) 2007-05-24
JP2009515556A (ja) 2009-04-16
AU2006315348A1 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
US20190361028A1 (en) Free ngal as a biomarker for cancer
US20090215102A1 (en) Method to Assess Breast Cancer Risk
US7858324B2 (en) Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
US20100209944A1 (en) Adamts-7 as a biomarker for cancers of epithelial origin
US20180156808A1 (en) Methods for diagnosis and prognosis of cancers of epithelial origin
US20260104417A1 (en) Use of urinary protein biomarkers to distinguish between neoplastic and non-neoplastic disease of the prostate
CN101346629A (zh) 评估乳癌风险的方法

Legal Events

Date Code Title Description
FZDE Discontinued